Panelists discuss how real-world comparisons of apalutamide and enzalutamide suggest survival trends influenced by tolerability, adherence, and patient selection rather than intrinsic drug differences ...
Fast track designation accelerates development of [68Ga]Ga-DPI-4452 for ccRCC detection, enhancing FDA engagement and review processes. ITM-94, a gallium-68-radiolabeled PET agent, forms a theranostic ...
Aaron R. Hansen, BSc, MBBS, FRACP, highlights key findings from the theraPb trial, exploring the safety and preliminary efficacy of ADVC001 in mCRPC. According to the authors, “ADVC001 is a novel PSMA ...
In an interview at the 2025 LUGPA Annual Meeting, Stacy Loeb, MD, shared key takeaways from her session, “Current state of prostate cancer screening.” Loeb is a urologists at NYU Langone Health in New ...
Across the board, the researchers' work offers answers that could transform guidelines, reduce invasive procedures, improve diagnostic accuracy, and empower clinicians with more personalized tools.
Aaron R. Hansen, BSc, MBBS, FRACP, highlights key findings from the theraPb trial, exploring the safety and preliminary efficacy of ADVC001 in mCRPC.
A panel of experts discusses the evolution of BPH treatment, as well as how their practices have been affected by COVID-19.
Dr Hamstra describes the three FDA-approved rectal spacers SpaceOAR, Barrigel, and BioProtect, noting differences in placement technique, advantages, potential risks, and the need for long-term ...
Low-intensity extracorporeal shock wave therapy is a safe treatment for men with erectile dysfunction and might work to improve, or even cure, ED in some patients. But there remain important ...
Anktiva is the first drug to rescue T and NK cells, crucial for cancer cell eradication and memory generation. The "triangle offense" involves NK cells, CD8 killer T cells, and memory T cells, forming ...
"We've been doing a lot of work at Johns Hopkins using high-dose testosterone therapies to treat patients with metastatic prostate cancer," says Mark C. Markowski, MD, PhD. In this interview, Mark C.
A new analysis supports return to widespread screening. A reevaluation of the tradeoffs of prostate cancer screening using the most recent data should rewrite the negative narrative associated with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback